Orphan Status for Alnylam Drug - Analyst Blog

By Zacks Equity Research,

Shutterstock photo

Alnylam Pharmaceuticals Inc . ( ALNY ) recently announced that its candidate ALN-TTR02 has been granted orphan drug status by the US Food and Drug Administration (FDA). ALN-TTR02 received orphan drug status to treat patients suffering from familial amyloidotic polyneuropathy (FAP). The disorder refers to one of the predominant clinical manifestations of transthyretin (TTR)-mediated amyloidosis (ATTR).

We note that the orphan drug designation is granted in the US only to drugs that treat a disease affecting less than 200,000 people in the country. Moreover, the orphan drug status for ALN-TTR02 provides Alnylam Pharma with seven years of marketing exclusivity (from the day ALN-TTR02 is cleared by the FDA) in the US for the indication.

We note that earlier this month, Alnylam announced the completion of enrollment in its phase I trial with ALN-TTR02. The company also initiated a phase II trial to evaluate clinical activity, safety, and tolerability of multiple once-monthly doses of ALN-TTR02 in patients suffering from ATTR. Apart from Alnylam, Pfizer (PFE) is also developing its candidate to treat TTR-FAP.

Apart from ALN-TTR02, Alnylam is also developing ALN-TTRsc, for the utilization of GalNAc-conjugate delivery technology and subcutaneous dose administration, into clinical development. The company intends to file a New Drug Application (IND) for ALN-TTRsc in the second half of 2012 with data expected in the first half of 2013. Furthermore, the company is developing ALN-RSV01 for the treatment of respiratory syncytial virus infection; ALN-VSP for the treatment of liver cancer and ALN-HTT for the treatment of Huntington's disease.

Our take

We currently have a Neutral recommendation on Alnylam. The stock carries a Zacks #2 Rank (Buy rating) in the short-run.

ALNYLAM PHARMA (ALNY): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

This article appears in: Investing , Business , Stocks
Referenced Stocks: ALNY , IND , PFE

More from Zacks.com




Follow on:

Find a Credit Card

Select a credit card product by:
Select an offer:
Data Provided by BankRate.com